February 24, 2006 – The FDA will take additional time to review Zostavax, a vaccine for shingles from Merck; Abbott introduced a new catheter that allows physicians to treat blockage in coronary arteries that previously required major surgery; Hollis-Eden completed its proposal to supply anti-radiation sickness drugs to the Project Bioshield stockpile; Baxter International received a UK contract for 2 million doses of avian flu vaccine; GPC Biotech raised 36.2 million euros in a placement with Dietmar Hopp, the owner of SAP; Inverness Medical Innovations will buy the immunoassay products business from ACON Labs for $175 million; DUSA Pharma announced positive data from a Phase II trial of a drug that treats sun damage on the skin; and Transition Therapeutics said its Alzheimer’s drug produced positive data in laboratory studies. The Centient Biotech 200™ was 33 points higher today, closing at 3993.10, a rise of .84%. More details...
